FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology and enables to treat Parkinson's disease. Method involves as follows. The baseline Parkinson's disease therapy is combined with oral introduction of antioxidant carnosine during 30 days as dosed 1.5 g daily.
EFFECT: introduction of carnosine as described above allows for reduced dopaminergic neuron injuries caused by oxidative stress ensured by higher superoxide dismutase activity.
1 ex, 1 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USING HEPTAPEPTIDE FOR TREATING PARKINSON'S DISEASE AND METHOD OF TREATING SUCH DISEASE | 2011 |
|
RU2450822C1 |
| METHOD FOR TREATING PARKINSON'S DISEASE | 2003 |
|
RU2255775C1 |
| METHOD FOR CURATIVE EFFECT ON PATIENT BODY IN TREATMENT OF PARKINSON'S DISEASE | 2002 |
|
RU2213565C1 |
| LIPOIC ACID MYCELIAL COMPLEX WITH CARNOSINE FOR MAMMALS PROTECTION AGAINST OXIDATIVE STRESS | 2016 |
|
RU2647435C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
| METHOD OF CORRECTION OF OXIDATIVE STATUS IN PARKINSON'S DISEASE IN EXPERIMENT | 2023 |
|
RU2800859C1 |
| LACTOBACILLUS FERMENTUM U-21 STRAIN, WHICH PRODUCES COMPLEX OF BIOLOGICALLY ACTIVE SUBSTANCES WHICH NEUTRALIZE SUPEROXIDE ANION INDUCED BY CHEMICAL AGENTS | 2018 |
|
RU2705250C2 |
| USE OF LACTOBACILLUS FERMENTUM U-21 STRAIN CELLS FOR PREVENTION OF PATHOLOGIC TISSUE CHANGE CAUSED BY OXIDATIVE STRESS | 2019 |
|
RU2757118C2 |
| METHOD OF REDUCING MANIFESTATION OF NON-MOTOR SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE | 2019 |
|
RU2734718C1 |
